Validation Data Shows Rosetta's Array-based CUP Test Outperforms PCR-based Predecessor | GenomeWeb

By Molika Ashford

Post-marketing validation of Rosetta Genomics' miRview Mets 2 has shown that the array-based test exhibited 88 percent concordance with clinical presentation and pathology on a set of cancer-of-unknown-primary samples, exceeding the accuracy of its predecessor PCR-based assay, miRview Mets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.